

HENRY A. WAXMAN, CALIFORNIA  
EDWARD J. MARKEY, MASSACHUSETTS  
RICK BOUCHER, VIRGINIA  
EDOLPHUS TOWNS, NEW YORK  
FRANK PALLONE, Jr., NEW JERSEY  
BART GORDON, TENNESSEE  
BOBBY L. RUSH, ILLINOIS  
ANNA G. ESHOO, CALIFORNIA  
BART STUPAK, MICHIGAN  
ELIOT L. ENGEL, NEW YORK  
ALBERT R. WYNN, MARYLAND  
GENE GREEN, TEXAS  
DIANA DeGETTE, COLORADO  
VICE CHAIRMAN  
LOIS CAPPS, CALIFORNIA  
MIKE DOYLE, PENNSYLVANIA  
JANE HARMAN, CALIFORNIA  
TOM ALLEN, MAINE  
JAN SCHAKOWSKY, ILLINOIS  
HILDA L. SOLIS, CALIFORNIA  
CHARLES A. GONZALEZ, TEXAS  
JAY INSLEE, WASHINGTON  
TAMMY BALDWIN, WISCONSIN  
MIKE ROSS, ARKANSAS  
DARLENE HOOLEY, OREGON  
ANTHONY D. WEINER, NEW YORK  
JIM MATHESON, UTAH  
G.K. BUTTERFIELD, NORTH CAROLINA  
CHARLIE MELANCON, LOUISIANA  
JOHN BARROW, GEORGIA  
BARON P. HILL, INDIANA

ONE HUNDRED TENTH CONGRESS

**U.S. House of Representatives**  
**Committee on Energy and Commerce**  
**Washington, DC 20515-6115**

JOHN D. DINGELL, MICHIGAN  
CHAIRMAN

JOE BARTON, TEXAS  
RANKING MEMBER  
RALPH M. HALL, TEXAS  
FRED UPTON, MICHIGAN  
CLIFF STEARNS, FLORIDA  
NATHAN DEAL, GEORGIA  
ED WHITFIELD, KENTUCKY  
BARBARA CUBIN, WYOMING  
JOHN SHIMKUS, ILLINOIS  
HEATHER WILSON, NEW MEXICO  
JOHN B. SHADEGG, ARIZONA  
CHARLES W. "CHIP" PICKERING, MISSISSIPPI  
VITO FOSSELLA, NEW YORK  
ROY BLUNT, MISSOURI  
STEVE BUYER, INDIANA  
GEORGE RADANOVICH, CALIFORNIA  
JOSEPH R. PITTS, PENNSYLVANIA  
MARY BONO MACK, CALIFORNIA  
GREG WALDEN, OREGON  
LEE TERRY, NEBRASKA  
MIKE FERGUSON, NEW JERSEY  
MIKE ROGERS, MICHIGAN  
SUE MYRICK, NORTH CAROLINA  
JOHN SULLIVAN, OKLAHOMA  
TIM MURPHY, PENNSYLVANIA  
MICHAEL C. BURGESS, TEXAS  
MARSHA BLACKBURN, TENNESSEE

March 6, 2008

DENNIS B. FITZGIBBONS, CHIEF OF STAFF  
GREGG A. ROTHSCHILD, CHIEF COUNSEL

The Honorable Andrew C. von Eschenbach, M.D.  
Commissioner  
U.S. Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

Dear Dr. von Eschenbach:

Under Rules X and XI of the Rules of the United States House of Representatives, the Committee on Energy and Commerce and its Subcommittee on Oversight and Investigations are investigating the ability of the Food and Drug Administration (FDA) to protect the American public from excessive risks associated with prescription drugs.

Early last year, the Committee became aware of troubling signs of safety problems in connection with a class of drugs known as Erythropoiesis-Stimulating Agents (ESAs), which are designed to prevent the need for blood transfusions in cancer and dialysis patients suffering from anemia. Since then, we have been increasingly alarmed by clinical study reports that indicate ESAs, also known as erythropoietin (EPO) products, cause increased blood clots and mortality, and may even enhance disease progression.

The Data Safety Monitoring Boards of a number of ESA clinical studies have recommended suspension of their studies because of heightened risk of harm to patients. In April 18, 2007, letters to this Committee, Johnson & Johnson, and Amgen listed 10 ESA clinical studies that were terminated or suspended because of unanticipated harm to patients: BEST Study; PR00-03-006; LEGACY Study; CHOIR Study; PR00-27-024; PR01-04-005, GOG 191; RTOG-99-20; EPO-CAN-20; DAHANCA 10; and Roche's study NH19960.

As a result, FDA issued a "black box" label warning last year on all drugs in the ESA class, citing heart and cancer risks and urging their use in the lowest dose possible that still helped patients avoid blood transfusions. Nevertheless, these drugs continue to be prescribed for indicated as well as off-label use. Indeed, Johnson & Johnson and Amgen, the manufacturers of

The Honorable Andrew C. von Eschenbach, M.D.

Page 2

manufacturers of these drugs, continue to invest millions of dollars into lobbying and marketing campaigns that misrepresent the risks associated with ESAs.

Furthermore, the dramatic findings of a recent meta-analysis of ESA data published in the Journal of the American Medical Association (JAMA) raise serious concerns about the risk profile of the entire class of ESA products, including Aranesp and Procrit. In the February 27, 2008, issue of JAMA, Charles L. Bennett, M.D., Ph.D., *et al.* found that even when used as directed, ESAs put cancer patients at nearly 57 percent increased risk of blood clots. Study researchers also reported that ESAs increase the risk of death in cancer patients by about 10 percent. The meta-analysis also discusses results of experiments that indicate use of ESAs could actually *enhance* cancer growth at the same time that doctors are using other drugs to control the disease.


We applaud the past efforts of FDA officials who have insisted on science and evidence-based decisions respecting use of ESA drugs. The analysis published in JAMA, however, along with the 10 clinical studies halted by Data Safety Boards and other negative safety data, suggest a need for reconsideration of the risk/benefit profile of this potentially dangerous class of drugs.

We urge FDA to use the scheduled Oncologic Drugs Advisory Committee meeting on March 13, 2008, to seriously reconsider the overall safety of ESAs and address the question of whether any demonstrable benefits of these drugs offset the evidence of increased mortality, blood clots, and tumor promotion.

Most importantly, we encourage FDA to act with due haste to avoid further endangering patients who may have been steered toward these drugs by aggressive marketing practices, including the use of misleading direct-to-consumer advertisements and recommendations from physicians who personally profit from the sale of these drugs.

Should you have any questions regarding these requests, please contact us or have your staff contact Joanne Royce or Paul Jung with Committee on Energy and Commerce staff at (202) 226-2424.

Sincerely,



John D. Dingell  
Chairman



Bart Stupak  
Chairman  
Subcommittee on Oversight and Investigations

The Honorable Andrew C. von Eschenbach, M.D.  
Page 3

cc: The Honorable Joe Barton, Ranking Member  
Committee on Energy and Commerce

The Honorable John Shimkus, Ranking Member  
Subcommittee on Oversight and Investigations